Trial NCT03326258

View at ClinicalTrials.gov 
Org. Study IDs: NCI-2017-01979
Secondary IDs: 10157 NCI-2017-01979 UM1CA186704

Last trial update was posted on 2018-07-18

MeSH Interventions

Antibodies Antibodies, Monoclonal Glembatumumab vedotin Immunoconjugates Immunoglobulins Immunotoxins Ipilimumab Nivolumab

MeSH Conditions

Breast Neoplasms Melanoma Melanoma, Cutaneous Malignant Neoplasms Skin Neoplasms Uveal Neoplasms

Other Conditions

Advanced Malignant Solid Neoplasm Estrogen Receptor Negative GPNMB Positive HER2/Neu Negative Metastatic Malignant Solid Neoplasm Metastatic Melanoma Progesterone Receptor Negative Stage III Breast Cancer AJCC v7 Stage III Cutaneous Melanoma AJCC v7 Stage III Uveal Melanoma AJCC v7 Stage IIIA Cutaneous Melanoma AJCC v7 Stage IIIB Cutaneous Melanoma AJCC v7 Stage IIIC Cutaneous Melanoma AJCC v7 Stage IV Breast Cancer AJCC v6 and v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 Stage IV Uveal Melanoma AJCC v7 Triple-Negative Breast Carcinoma Unresectable Solid Neoplasm

Stopping Reasons

The study itself was Disapproved on 04/20/2018 and will not be moving forward.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID